Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEffect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis
Clinical Therapeutics, 10/29/09
Kampmann C et al. – Treatment with agalsidase alfa for 12 or 36 months was associated with reduced LVM in these patients with Fabry disease with baseline LVH, and it appeared to stabilize LVM in these patients without baseline LVH.
Related Articles
A case of minimal change disease in a Fabry patient
Pediatric Nephrology, 11/04/09
Relevance Score: 88%
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL? for Fabry Disease with U.S. FDA
Shire, 10/22/09
Relevance Score: 88%
Genetics: Hypertrophic cardiomyopathy
Canadian Family Physician, 11/16/09
Relevance Score: 87%
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09
Relevance Score: 81%
Hormone replacement therapy benefits postmenopausal women
Internet Source, 10/09/09
Relevance Score: 81%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
The role of pulmonary veins in atrial fibrillation
Pharmacology & Therapeutics, 11/24/09
Telmisartan prevents cardiovascular events in a broad group of at-risk patients
Expert Opinion in Pharmacotherapy, 11/23/09
Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events
European Heart Journal, 11/23/09
Sponsor
Article Search
Sponsor